Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969032 | 0.83 | CYP1A2 (0.60) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL3396050 | 0.81 | CYP1A2 (0.58) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL526457 | 0.81 | CYP1A2 (0.58) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL28589683 | 0.81 | CYP1A2 (0.58) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL3294354 | 0.81 | KMT2A (0.50) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL9827778 | 0.80 | CYP1A2 (0.39) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL13777688 | 0.80 | KDM4E (0.62) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL28586067 | 0.80 | MAPT (0.57) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL6089983 | 0.79 | KMT2A (0.48) | CYP1A2KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL15046538 | 0.79 | CYP1A2 (0.55) | CYP1A2BACE1PDE10AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105622609-B | A kind of Li Gelieting preparation method | 上海万巷制药有限公司 | 2017-08-25 | — | — | CN | claimed |
| CN-105622609-B | A kind of Li Gelieting preparation method | 上海万巷制药有限公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-103319483-B | A kind of preparation method of important intermediate of linagliptin | 药源药物化学（上海）有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-RE40558-E1 | Therapeutic uses of di-aryl acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| EP-0784052-B1 | Quinoline derivatives as antagonists of leukotriene d4, compositions containing the same and processes for their preparation | AVENTIS HOLDINGS INC (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6635655-B1 | Agonists or antagonists of peroxisome proliferator-activated receptors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-21 | — | — | US | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1030665-A4 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-1177187-A1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0349062-A1 | Quinoline ether alkanoic acid | MERCK FROSST CANADA INC. (CA) | 1990-01-03 | — | — | EP | disclosed |
| WO-1989012628-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0348155-A1 | Quinoline derivatives as antagonists of leukotriene D4, compositions containing the same and processes for their preparation | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-12-27 | — | — | EP | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| WO-1989004303-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0260305-A4 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS. | RORER INTERNAT OVERSEAS INC (US) | 1988-07-04 | — | — | EP | disclosed |
| EP-0261539-A2 | Substituted phenyl-sulphon amides | BAYER AG (DE) | 1988-03-30 | — | — | EP | disclosed |
| EP-0260305-A1 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS. | RORER INT OVERSEAS (US) | 1988-03-23 | — | — | EP | disclosed |
| WO-1987005510-A1 | QUINOLINYL ETHER OR THIOETHER TETRAZOLES AS AGENTS FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-09-24 | — | — | WO | disclosed |